Syndax Pharmaceuticals Inc. (SNDX) on a Strong Footing amid Robust Demand for Key Flagship Drugs

The institution generated $125 cardinal successful yearly nett income for Revuforj and $152 cardinal for Niktimvo successful the archetypal 11 months. Consequently, the products are showing quarter-over-quarter income growth. Revuforj’s gross maturation is driven by continued penetration successful its labeled denotation for KMT2A-rearranged acute myeloid leukemia.

In addition, the institution is staring astatine a tremendous accidental with Niktimvo successful chronic GVHD, targeting 6,500 patients that could grow to astir 17,000. Consequently, the institution could make up to $1 cardinal successful third-line positive sales. Syndax has a strategical collaboration with Incyte to co-promote the product.

Syndax Pharmaceuticals (NASDAQ:SNDX) is simply a commercial-stage biopharmaceutical institution focused connected processing and commercializing innovative, first-in-class, targeted therapies for cancer, peculiarly acute leukemia and chronic graft-versus-host illness (cGVHD). They are known for FDA-approved drugs Revuforj (revumenib) and Niktimvo (axatilimab-csfr).

While we admit the imaginable of SNDX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 13 Best Manufacturing Stocks to Invest In Now and 11 AI Stocks That Will Go to the Moon.

Disclosure: None.  Follow Insider Monkey connected Google News.